This is not totally unexpected, but it does put the possibility of a partnership (and any new strong data since the april update) off the table, so some modest hit to the share price is likely tomorrow JMO I'm glad to get it over with and extend the cash runway I think the drug has a reasonable chance of success particularly in patients with low tumor burdern
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.